[Cefepime/amikacin in the empirical antibacterial therapy for patients with hemoblastosis of different forms]

Area of Science:

• Hematology
• Infectious Diseases
• Pharmacology

Background:

• Patients with hemoblastosis undergoing chemotherapy often experience severe infections due to prolonged neutropenia.
• High-risk patients with neutrophil counts below 100 cells/microliter are particularly susceptible to infectious complications.

Purpose of the Study:

• To compare the efficacy of cefepime plus amikacin versus ceftriaxone plus amikacin in treating severe infections in hemoblastosis patients.
• To evaluate treatment outcomes in a high-risk neutropenic patient population.

Main Methods:

• A comparative study involving 80 patients with various forms of hemoblastosis and severe infectious complications.
• Patients were randomized to receive either cefepime and amikacin or ceftriaxone and amikacin.
• Treatment duration and success rates were recorded for both groups.

Main Results:

• The cefepime + amikacin group achieved a success rate of 95% (38/40 patients) over an average of 13 days.
• The ceftriaxone + amikacin group had a success rate of 60% (24/40 patients) over an average of 14 days.
• Both treatment regimens were administered to patients experiencing neutropenia for an average of 12 days.

Conclusions:

• Cefepime in combination with amikacin is a more effective treatment for severe infections in hemoblastosis patients with neutropenia compared to ceftriaxone plus amikacin.
• This combination therapy offers a higher success rate, potentially improving outcomes for high-risk cancer patients.